Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)
Heikki Joensuu(Orion Corporation (Finland)), Henrik Lindman(Uppsala University), Lotta Lundgren(Skåne University Hospital), Päivi Halonen(University of Helsinki), Helena Granstam-Björneklett(Västerås Municipality), Päivi Auvinen(University of Eastern Finland), Paul Nyandoto(Päijät-Hämeen Keskussairaala), Hans Wildiers(KU Leuven), Riikka Huovinen(Turku University Hospital), Meri Utriainen(University of Helsinki), P. Neven(University of Helsinki), Tuomas T. Huttunen(Tampere University), Jennifer A. Fraser(Edinburgh Napier University), VJ Harvey, KK Villman(University of Helsinki), Peter Canney(Beatson West of Scotland Cancer Centre), P-L Kellokumpu-Lehtinen(Uppsala University Hospital), Jeffrey Yachnin(Karolinska University Hospital), Diana Ritchie(Beatson West of Scotland Cancer Centre), Taina Turpeenniemi‐Hujanen(Oulu University Hospital)
Cited by 12
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k